Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Quinolone can combat 22 new pathogens, FDA says
Fort Worth, TX-Alcon Inc. is adding 22 susceptible pathogens to its moxifloxacin HCl 0.5% ophthalmic solution (Vigamox) in vitro labeling. The additions, which the FDA approved in late April, include atypical mycobacteria and Propionibacterium acnes. Alcon said its fourth-generation fluoroquinolone eye drop now offers the broadest spectrum in the ophthalmic fluoroquinolone category.
Related Videos
Related Content
